mobio.org
  • Donald Danforth Plant Science Center

    Your Only Statewide Network

    Donald Danforth Plant Science Center

    Your Only Statewide Network

  • Bond Life Sciences Center

    Your Voice For Missouri Life Sciences

  • Jordan Valley Innovation Center

    Business Savings Plans

  • Washington University in St. Louis - School of Medicine

    Your Only Statewide Network

  • MRIGlobal

    Your Voice For Missouri Life Sciences

  • Bayer Crop Science

    Business Savings Plans

MISSOURI BIOTECHNOLOGY ASSOCIATION - WHAT WE DO

Missouri Biotechnology Association (MOBIO) is the only statewide membership group that speaks with one voice to advance and champion the life sciences in Jefferson City, across the state, and in Washington, D.C. MOBIO represents most extensive and broadest cross-section of life science organizations including businesses, higher education, medical research, start-ups, agri-science and related firms involved in research, development, and commercialization of the life sciences. MOBIO serves to connect, develop, and advance the state’s bioscience community.

MOBIO members benefit from a strategic focus to support the enrichment and growth of the biosciences in Missouri through:

Statewide Network

MOBIO connections make a difference, specializing in meaningful business-to-business engagements and bridging: 

  • A network of diversified thought leaders
  • Business leaders with policymakers
  • Entrepreneurs with investors
  • Members to greater market potential 


Members connect at regional, national, and international levels with science, education, and commercial networks to advance business and enrich the industry. 


MOBIO is the catalyst, accelerating growth and leveraging high-value relationships for our vibrant life sciences community. 

Science & Policy

MOBIO advocates for Missouri’s life sciences and technology sectors.  Maintaining a sophisticated understanding of current dynamics, MOBIO serves as your trusted voice for bipartisan engagement and leadership within the Missouri State Capitol.

  • MOBIO forges meaningful relationships between public and private sector leaders to:
  • Defend companies large and small
  • Obtain and safeguard public investment
  • Secure state funding for Missouri's life science industry 


The strength of MOBIO's collective voice consistently delivers a compelling message to advance pro-science, pro-business legislative policy.    

Member Savings

MOBIO saves members real money, providing access to numerous partner organizations that offer significant discounts on relevant industry products and services.

  • R & D
  • Laboratory
  • Finance & Administration
  • Facilities & Operations
  • Communications & Data


All MOBIO members are entitled to preferred purchasing power. There is NO fee to participate.

MOBIO Member Highlight

 

Immunophotonics, Inc.

4340 Duncan Avenue

BioGenerator Labs, Suite 212

St. Louis, MO 63110

info@immunophotonics.com

www.immunophotonics.com

 

Immunophotonics is a US-based privately owned clinical stage (Phase 1/2) biotech company developing a first-in-class drug (IP-001) to address the major problem of tumor recurrence after first-line locoregional procedures. A large portion of patients will have tumor recurrences, often in distant locations and organs, at which point the disease becomes much more difficult to treat.

 

IP-001 is designed to drive a tumor-specific adaptive immune response against the micrometastases that lead to disease progression by utilizing tumor-associated antigens released by first-line locoregional therapies (>50% of all cancer patients will receive radiation or ablation with "curative intent" during their treatment journey).

CLINICAL TRIALS

Investigator-driven trials and a phase 1b trial in Switzerland have demonstrated a favorable toxicity profile and showed early clinical signals that IP-001 is including a systemic anti-tumor immune response. The company is actively recruiting patients in the US, Switzerland, France, Germany, and the UK in two Phase 1b/2a clinical trials in very advanced cancer patients (NCT05688280, NCT03993678). Collectively, clinical trial data has shown excellent safety and tolerability across all indications, and preliminary data indicates that IP-001 can increase T cell trafficking systemically and has also demonstrated anti-tumor activity, without changing the existing workflow in the clinic.


Immunophotonics is currently initiating two Phase 2 investigator-sponsored clinical trials in target patient populations (IP-001 as adjuvant therapy to standard-of-care ablation with curative intent; readouts will be recurrence-free survival). The company is also in discussions with the largest interventional oncology organization in the world to start preparations for a pivotal Phase 2/3 trial.

 

COLLABORATIONS

Research Collaboration with Johnson & Johnson Enterprise Innovation Inc.
Immunophotonics recently made headlines with the announcement of a groundbreaking collaboration with Johnson & Johnson Enterprise Innovation (JJEI), marking a significant milestone for the company. This strategic partnership brings together Immunophotonics' expertise in developing cutting-edge immuno-oncology treatments with Johnson & Johnson's renowned resources and global reach in healthcare innovation. The collaboration is to explore the use of radiation to destroy tumors with IP-001, Immunophotonics' immunotherapy drug. With this collaboration, Immunophotonics and Johnson & Johnson are poised to drive forward the frontier of radiation therapy for cancer by coupling radiation-induced tumor death with IP-001-induced anticancer immune activation.

Link to press release: Immunophotonics Announces Research Collaboration to Study Combination of Its Lead Asset with Radiotherapy (einpresswire.com)

 

Partnership with AngioDynamics to Explore the Power of Immunotherapy

Immunophotonics recently announced a partnership that will combine use of Immunophotonics’ lead asset, IP-001 and AngioDynamics’ ablation devices to explore the power of ablation in combination with immunotherapy for the treatment of solid tumor cancers. This collaborative effort extends to a partnership with the Cancer Center Amsterdam at Amsterdam University Medical Center (Amsterdam UMC) in the Netherlands. 

 

Link to press release: https://www.einpresswire.com/article/691520924/angiodynamics-and-immunophotonics-announces-partnership-to-explore-the-power-of-immunotherapy

MOBIO Breakthrough

Join us for MOBIO's Breakthrough of the Month series, where we explore Missouri's new and sometimes hidden biotech industry.  


This is a virtual learning platform for the greater life science community where we highlight and discuss novel discoveries, new business opportunities, and potential partnerships. 


This is a FREE presentation that is open to those in the life-science community. 


Are you interested in featuring your organization or discovery?  Please reach out to us, via email.

Tell Your Story

Please schedule your organization or recommend an area of interest.

Recordings

Miss a Breakthrough?  No problem, monthly recordings are archived for your convenience.

Share

Invite a coworker or colleague to attend.